ESSA Pharma Inc.

1.79
0.02 (1.13%)
At close: Apr 17, 2025, 3:59 PM
1.80
0.35%
After-hours: Apr 17, 2025, 06:35 PM EDT
1.13%
Bid 1.75
Market Cap 79.46M
Revenue (ttm) n/a
Net Income (ttm) -31.11M
EPS (ttm) -0.69
PE Ratio (ttm) -2.59
Forward PE -3.64
Analyst Hold
Ask 1.87
Volume 177,575
Avg. Volume (20D) 180,893
Open 1.77
Previous Close 1.77
Day's Range 1.73 - 1.81
52-Week Range 1.40 - 7.88
Beta 1.61

About EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and A...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 13, 2015
Employees 35
Stock Exchange NASDAQ
Ticker Symbol EPIX
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for EPIX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 11.73% from the latest price.

Stock Forecasts
3 days ago
+8.59%
ESSA Pharma shares are trading higher after disclo... Unlock content with Pro Subscription
5 months ago
-73.08%
ESSA Pharma shares are trading lower after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC